What Is Hepatitis C?

Hepatitis C is a viral infection caused by the hepatitis C virus (HCV). It primarily affects the liver and often leads to chronic illness. Many people infected with HCV initially have no symptoms. Over time, the infection can cause progressive liver damage that may result in cirrhosis, liver failure, or liver cancer.

Am I at Risk?

Anyone exposed to the virus through blood-to-blood contact, such as sharing needles, unsafe medical equipment, or transfusions before 1992, may be at risk. Injection drug users, those with tattoos done in unregulated settings, hemodialysis patients, and individuals previously incarcerated are also at higher risk. Screening is recommended for all adults aged 18 to 79 in the U.S. 

How Is Hepatitis C Diagnosed?

Diagnosis begins with a blood test that checks for antibodies to HCV. If positive, a confirmatory test using HCV RNA polymerase chain reaction (PCR) determines whether the virus is actively present. Since antibodies can persist after infection has resolved, and may not appear immediately, PCR testing is essential to confirm an active infection. 

For some cases, especially chronic infections, a liver biopsy may be used to assess the extent of liver damage. However, non-invasive blood tests or imaging tools are increasingly preferred for evaluating fibrosis.

Who Should Be Screened?

Routine screening is advised for all adults aged 18–79, regardless of symptoms. Because most chronic infections are initially asymptomatic, elevated liver enzymes discovered on routine labs may prompt testing. Additional criteria, including injection drug use, past transfusions, tattoos in unregulated settings, or long-term hemodialysis, also warrant HCV testing. 

How Is Hepatitis C Treated?

Current treatment for chronic hepatitis C involves direct-acting antiviral (DAA) medications such as sofosbuvir, velpatasvir, glecaprevir, pibrentasvir, ledipasvir, and others. These medications target different HCV genotypes and typically are taken for 8 to 12 weeks. Cure rates exceed 95% in most patients, including those with cirrhosis.

Treatment choice depends on HCV genotype, liver health, prior treatments, and presence of cirrhosis. For example:

• Genotype 1a (without cirrhosis): 8-week regimens of glecaprevir/pibrentasvir or ledipasvir/sofosbuvir.
• Genotype 3 with cirrhosis: 12-week courses of SOF/VEL or possibly SOF/VEL/VOX if resistance-associated variants are present.

Preparation & Aftercare

Before starting therapy, your provider will assess liver function, genotype of HCV, and whether cirrhosis is present. Those with cirrhosis require surveillance for complications like esophageal varices. If varices are found, upper endoscopy is repeated annually or every two years, depending on severity. 

Care includes:

• Avoiding alcohol and liver-toxic medications,
• Receiving vaccinations for hepatitis A and B if not immune,
• Monitoring liver health post-treatment to ensure sustained viral response (SVR).

Effectiveness & Outcomes

DAA treatments are highly effective, with cure rates over 95%. Achieving a sustained viral response—defined as no detectable HCV RNA at least 24 weeks after treatment—dramatically reduces the risk of liver cancer. Even individuals with cirrhosis often qualify for curative therapy. 

Risks & Comparison to Other Treatments

Direct-acting antivirals are well tolerated, with fewer side effects compared to older regimens like interferon and ribavirin. Interferon-based treatments were slower, less effective, and caused flu-like symptoms or depression in many patients. DAAs typically involve only mild side effects such as fatigue or headache. 

Advantages & Limitations

Advantages:

• Short oral regimens (8–12 weeks),
• Cure rates exceeding 95% for nearly all genotypes,
• Minimal side effects,
• Available generic options that have reduced cost barriers.

Limitations:

• Cost can still be a barrier in some cases,
• Access to newer antivirals may depend on healthcare coverage,
• People with advanced liver disease may still need surveillance post-cure.

What to Expect & Follow-Up

Your provider may repeat HCV RNA testing 12 weeks after treatment ends to confirm SVR. If cured, routine monitoring of liver function continues, especially for those with cirrhosis who are at ongoing risk of liver cancer or varices. Esophageal endoscopy may be advised every 1–2 years, depending on the presence and size of varices.  

Glossary of Terms

• HCV (Hepatitis C Virus): The virus that causes hepatitis C infection.
• Direct‑acting antivirals (DAAs): Medications that block viral replication and target different genotypes.
• Sustained viral response (SVR): No detectable HCV in blood at least 24 weeks after completing therapy, considered a cure.
• Genotype: The strain of HCV (such as type 1a, 1b, 2, 3, 4, etc.) that affects treatment choice.
• Cirrhosis: Scarring of the liver from long-term damage, which can impair function and increase cancer risk.
• Varices: Enlarged veins in the esophagus or stomach, often a result of cirrhosis.
• PCR (Polymerase chain reaction): A test that detects active viral genetic material in the blood.

Conclusion

Modern treatment for hepatitis C is highly effective, well tolerated, and able to cure most patients with chronic infection. Early diagnosis and prompt therapy can prevent long-term complications such as cirrhosis and liver cancer. If you have risk factors or elevated liver enzymes, ask your provider whether hepatitis C testing is appropriate. With SVR, most patients can expect a significant improvement in liver health and long-term well‑being.